RxDoctor Payments Data

Dana Mello

Adult Health · Plant City, FLNPI 1568943629

Payments from drug & device makers

$9,686in general payments, 2019–2025

Across 326 payments — averaging $29.71 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$2K
  • Endologix LLC$2K
  • AbbVie$1K
  • Sanofi$770
  • QOL Medical, LLC$598
  • Madrigal Pharmaceuticals$354
  • plus $3K from 26 others

What the payments were for

  • Consulting fees$1,35014%
  • Food & beverage$8,16784%
  • Education$1702%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,686 in reported general payments places this provider in the 95th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$39,298
Medicare patients
233
Services billed
385

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RezdiffraResmetirom19$75,321
XifaxanRifaximin22$73,239
LinzessLinaclotide77$68,158
ZenpepLipase/Protease/Amylase25$68,126
CreonLipase/Protease/Amylase12$60,884
IbsrelaTenapanor Hcl15$25,804
Colestipol Hcl58$4,132
Sucralfate64$3,948
Pantoprazole Sodium219$3,674
Famotidine264$3,548
Dicyclomine Hcl130$2,904
Omeprazole163$2,652
Lubiprostone22$2,621
Ondansetron OdtOndansetron52$1,817
Esomeprazole Magnesium37$970

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess, Creon$1,034$129,04389 claims
Madrigal PharmaceuticalsRezdiffra$354$75,32119 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$143$73,23922 claims
Aimmune Therapeutics, Inc.Zenpep$30$68,12625 claims
Ardelyx, Inc.Ibsrela$156$25,80415 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,237 adult health providers in Florida.

Other adult health in Plant City

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →